Article
Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.
Journal of virology - 1 Oct 1994
Schlienger K, Montefiori D C, Mancini M, Rivière Y, Tiollais P, Michel M L
Abstract excerpt
The potential of the simian immunodeficiency virus (SIV) variable 2 (V2) domain as an effective region to boost SIV-neutralizing antibodies and to protect against live SIV challenge was tested in rhesus macaques. In this study, two rhesus macaques were primed with vaccinia virus recombinants expressing the surface glycoprotein gp140 of SIVmac and were given booster injections with the SIVmac V2 domain presented...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.